(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme a and response to atorvastatin in coronary artery disease patients

Viviana Noriega, Christian Pennanen, María Pilar Sánchez, Mario Chiong, Marcelo Llancaqueo, Sergio Lavandero, Juan Carlos Prieto

Resultado de la investigación: Article

5 Citas (Scopus)

Resumen

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors have been used clinically for lowering total and low-density lipoprotein cholesterol. Interindividual pharmacological differences observed with this treatment have been attributed to genetic differences. The aim of this study was to assess the association in the low-density lipoprotein cholesterol reduction by atorvastatin and (TTA)n polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene in patients with coronary artery disease. Changes in total cholesterol levels, triglycerides, high-sensitivity C-reactive protein and free F 2-isoprostanes were also evaluated. In an open study, patients received 40 mg atorvastatin daily for 8 weeks. Genotyping was done through polymerase chain reaction. The genotype distribution of the 3-hydroxy-3- methylglutaryl-coenzyme A reductase (TTA)n polymorphism was: >10/>10 in 22 out of 64 patients (34%), >10/10 in 14 out of 64 patients (22%) and 10/10 in 28 out of 64 patients (44%). The reduction of low-density lipoprotein cholesterol levels by atorvastatin was not different between allelic variants (TTA)n repeat polymorphism. Reductions in high-sensitivity C-reactive protein were observed in atorvastatin-treated patients with alleles >10/>10 and 10/10. Free F 2-isoprostanes and total cholesterol were also significantly lower after treatment for all alleles, irrespective of type of polymorphism. In conclusion, the changes induced by atorvastatin treatment on low-density lipoprotein cholesterol, total cholesterol, triglycerides, high-sensitivity C-reactive protein and free F 2-isoprostane concentrations were not related to the presence of 3-hydroxy-3-methylglutaryl- coenzyme A reductase polymorphism (TTA)n.

Idioma originalEnglish
Páginas (desde-hasta)211-215
Número de páginas5
PublicaciónBasic and Clinical Pharmacology and Toxicology
Volumen104
N.º3
DOI
EstadoPublished - mar 2009

Huella dactilar

Coenzymes
Polymorphism
Coronary Artery Disease
Isoprostanes
LDL Cholesterol
Oxidoreductases
C-Reactive Protein
Cholesterol
Triglycerides
Alleles
Polymerase chain reaction
Hypercholesterolemia
Genes
Atorvastatin Calcium
Association reactions
Therapeutics
Genotype
Pharmacology
3-hydroxy-3-methylglutaryl-coenzyme A
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology
  • Medicine(all)

Citar esto

Noriega, Viviana ; Pennanen, Christian ; Sánchez, María Pilar ; Chiong, Mario ; Llancaqueo, Marcelo ; Lavandero, Sergio ; Prieto, Juan Carlos. / (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme a and response to atorvastatin in coronary artery disease patients. En: Basic and Clinical Pharmacology and Toxicology. 2009 ; Vol. 104, N.º 3. pp. 211-215.
@article{d73c92f7249a4a6da0bfd24283abdcbd,
title = "(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme a and response to atorvastatin in coronary artery disease patients",
abstract = "3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors have been used clinically for lowering total and low-density lipoprotein cholesterol. Interindividual pharmacological differences observed with this treatment have been attributed to genetic differences. The aim of this study was to assess the association in the low-density lipoprotein cholesterol reduction by atorvastatin and (TTA)n polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene in patients with coronary artery disease. Changes in total cholesterol levels, triglycerides, high-sensitivity C-reactive protein and free F 2-isoprostanes were also evaluated. In an open study, patients received 40 mg atorvastatin daily for 8 weeks. Genotyping was done through polymerase chain reaction. The genotype distribution of the 3-hydroxy-3- methylglutaryl-coenzyme A reductase (TTA)n polymorphism was: >10/>10 in 22 out of 64 patients (34{\%}), >10/10 in 14 out of 64 patients (22{\%}) and 10/10 in 28 out of 64 patients (44{\%}). The reduction of low-density lipoprotein cholesterol levels by atorvastatin was not different between allelic variants (TTA)n repeat polymorphism. Reductions in high-sensitivity C-reactive protein were observed in atorvastatin-treated patients with alleles >10/>10 and 10/10. Free F 2-isoprostanes and total cholesterol were also significantly lower after treatment for all alleles, irrespective of type of polymorphism. In conclusion, the changes induced by atorvastatin treatment on low-density lipoprotein cholesterol, total cholesterol, triglycerides, high-sensitivity C-reactive protein and free F 2-isoprostane concentrations were not related to the presence of 3-hydroxy-3-methylglutaryl- coenzyme A reductase polymorphism (TTA)n.",
author = "Viviana Noriega and Christian Pennanen and S{\'a}nchez, {Mar{\'i}a Pilar} and Mario Chiong and Marcelo Llancaqueo and Sergio Lavandero and Prieto, {Juan Carlos}",
year = "2009",
month = "3",
doi = "10.1111/j.1742-7843.2008.00341.x",
language = "English",
volume = "104",
pages = "211--215",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "3",

}

(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme a and response to atorvastatin in coronary artery disease patients. / Noriega, Viviana; Pennanen, Christian; Sánchez, María Pilar; Chiong, Mario; Llancaqueo, Marcelo; Lavandero, Sergio; Prieto, Juan Carlos.

En: Basic and Clinical Pharmacology and Toxicology, Vol. 104, N.º 3, 03.2009, p. 211-215.

Resultado de la investigación: Article

TY - JOUR

T1 - (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme a and response to atorvastatin in coronary artery disease patients

AU - Noriega, Viviana

AU - Pennanen, Christian

AU - Sánchez, María Pilar

AU - Chiong, Mario

AU - Llancaqueo, Marcelo

AU - Lavandero, Sergio

AU - Prieto, Juan Carlos

PY - 2009/3

Y1 - 2009/3

N2 - 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors have been used clinically for lowering total and low-density lipoprotein cholesterol. Interindividual pharmacological differences observed with this treatment have been attributed to genetic differences. The aim of this study was to assess the association in the low-density lipoprotein cholesterol reduction by atorvastatin and (TTA)n polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene in patients with coronary artery disease. Changes in total cholesterol levels, triglycerides, high-sensitivity C-reactive protein and free F 2-isoprostanes were also evaluated. In an open study, patients received 40 mg atorvastatin daily for 8 weeks. Genotyping was done through polymerase chain reaction. The genotype distribution of the 3-hydroxy-3- methylglutaryl-coenzyme A reductase (TTA)n polymorphism was: >10/>10 in 22 out of 64 patients (34%), >10/10 in 14 out of 64 patients (22%) and 10/10 in 28 out of 64 patients (44%). The reduction of low-density lipoprotein cholesterol levels by atorvastatin was not different between allelic variants (TTA)n repeat polymorphism. Reductions in high-sensitivity C-reactive protein were observed in atorvastatin-treated patients with alleles >10/>10 and 10/10. Free F 2-isoprostanes and total cholesterol were also significantly lower after treatment for all alleles, irrespective of type of polymorphism. In conclusion, the changes induced by atorvastatin treatment on low-density lipoprotein cholesterol, total cholesterol, triglycerides, high-sensitivity C-reactive protein and free F 2-isoprostane concentrations were not related to the presence of 3-hydroxy-3-methylglutaryl- coenzyme A reductase polymorphism (TTA)n.

AB - 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors have been used clinically for lowering total and low-density lipoprotein cholesterol. Interindividual pharmacological differences observed with this treatment have been attributed to genetic differences. The aim of this study was to assess the association in the low-density lipoprotein cholesterol reduction by atorvastatin and (TTA)n polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene in patients with coronary artery disease. Changes in total cholesterol levels, triglycerides, high-sensitivity C-reactive protein and free F 2-isoprostanes were also evaluated. In an open study, patients received 40 mg atorvastatin daily for 8 weeks. Genotyping was done through polymerase chain reaction. The genotype distribution of the 3-hydroxy-3- methylglutaryl-coenzyme A reductase (TTA)n polymorphism was: >10/>10 in 22 out of 64 patients (34%), >10/10 in 14 out of 64 patients (22%) and 10/10 in 28 out of 64 patients (44%). The reduction of low-density lipoprotein cholesterol levels by atorvastatin was not different between allelic variants (TTA)n repeat polymorphism. Reductions in high-sensitivity C-reactive protein were observed in atorvastatin-treated patients with alleles >10/>10 and 10/10. Free F 2-isoprostanes and total cholesterol were also significantly lower after treatment for all alleles, irrespective of type of polymorphism. In conclusion, the changes induced by atorvastatin treatment on low-density lipoprotein cholesterol, total cholesterol, triglycerides, high-sensitivity C-reactive protein and free F 2-isoprostane concentrations were not related to the presence of 3-hydroxy-3-methylglutaryl- coenzyme A reductase polymorphism (TTA)n.

UR - http://www.scopus.com/inward/record.url?scp=60349125945&partnerID=8YFLogxK

U2 - 10.1111/j.1742-7843.2008.00341.x

DO - 10.1111/j.1742-7843.2008.00341.x

M3 - Article

C2 - 19067673

AN - SCOPUS:60349125945

VL - 104

SP - 211

EP - 215

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 3

ER -